LAVA Therapeutics NV
NASDAQ:LVTX

Watchlist Manager
LAVA Therapeutics NV Logo
LAVA Therapeutics NV
NASDAQ:LVTX
Watchlist
Price: 1.27 USD -1.55%
Market Cap: 33.4m USD

EV/EBITDA
Enterprise Value to EBITDA

1.5
Current
1.1
Median
4
Industry
Higher than median
Lower than industry value

Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.

EV/EBITDA
1.5
=
Enterprise Value
-39.6m USD
/
EBITDA
-27m USD
EBITDA Growth EV/EBITDA to Growth
NL
LAVA Therapeutics NV
NASDAQ:LVTX
Average EV/EBITDA: 51.4
1.5
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -211 598.4 N/A N/A
US
Abbvie Inc
NYSE:ABBV
17.1
13%
1.3
US
Amgen Inc
NASDAQ:AMGN
16.5
17%
1
US
Gilead Sciences Inc
NASDAQ:GILD
11.4
7%
1.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
25.4
17%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -534 N/A N/A
AU
CSL Ltd
ASX:CSL
17.1
11%
1.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
10.2
14%
0.7
US
S
Seagen Inc
F:SGT
Negative Multiple: -61 N/A N/A
NL
argenx SE
XBRU:ARGX
312.3
166%
1.9

EV/EBITDA Forward Multiples

Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBITDA
1.4
2-Years Forward
EV/EBITDA
1.2
3-Years Forward
EV/EBITDA
N/A